Profile data is unavailable for this security.
About the company
VCANBIO CELL & GENE ENGINEERING CORP., LTD is a China-based company, principally engaged in the preparation, detection and storage of cells. The Company is also engaged in cell culture and gene detection and storage, as well as the production and sale of cytokines culture solutions, cosmetics and detection reagents. The Company conducts its businesses mainly within domestic markets.
- Revenue in CNY (TTM)1.61bn
- Net income in CNY109.23m
- Incorporated1995
- Employees2.21k
- LocationVcanbio Cell & Gene Engineering Corp LtdNo.45 Dongjiu AvenueAirport Economic AreaTIANJIN 300384ChinaCHN
- Phone+86 2 258617160
- Fax+86 2 258617161
- Websitehttp://www.vcanbio.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Guangxi Wuzhou Zhongheng Group Co Ltd | 3.23bn | 156.14m | 8.49bn | 2.89k | 54.16 | 1.29 | -- | 2.63 | 0.0454 | 0.0454 | 0.9413 | 1.91 | 0.2766 | 1.96 | 3.41 | 1,120,149.00 | 0.9542 | 2.26 | 1.51 | 3.38 | 53.66 | 72.05 | 3.45 | 7.27 | 2.38 | -- | 0.1795 | 45.67 | 14.10 | -1.26 | 6.69 | -32.76 | -4.56 | -30.12 |
| Vcanbio Cell & Gene Engineering Corp Ltd | 1.61bn | 109.23m | 8.69bn | 2.21k | 79.51 | 2.36 | -- | 5.39 | 0.2334 | 0.2334 | 3.44 | 7.88 | 0.3034 | 2.01 | 2.86 | 728,818.10 | 1.97 | 1.13 | 2.79 | 1.61 | 67.97 | 67.76 | 6.51 | 3.84 | 1.52 | 6.93 | 0.0284 | 0.00 | 2.24 | 3.78 | -5.78 | 12.43 | -7.11 | -- |
| Lushang Freda Pharmaceutical Co Ltd | 4.20bn | 233.09m | 8.82bn | 3.65k | 37.86 | 2.17 | -- | 2.10 | 0.2293 | 0.2293 | 4.13 | 4.01 | 0.4446 | 0.8832 | 7.75 | 1,149,606.00 | 3.02 | 0.6992 | 5.84 | 5.12 | 48.44 | 20.23 | 6.79 | 3.45 | 2.67 | -- | 0.1251 | 40.33 | -64.65 | -12.29 | 567.44 | 13.36 | 44.40 | 14.87 |
| Shenzhen Lifotronic Technology Co Ltd | 1.17bn | 347.69m | 8.84bn | 1.48k | 25.43 | 4.63 | -- | 7.53 | 0.8120 | 0.8120 | 2.75 | 4.46 | 0.5409 | 2.32 | 7.90 | 792,478.60 | 15.97 | 13.82 | 19.66 | 16.33 | 65.70 | 61.01 | 29.52 | 26.10 | 3.51 | -- | 0.1004 | 41.51 | 16.55 | 28.78 | 30.66 | 32.27 | -7.91 | -- |
| Wuhan Keqian Biology Co Ltd | 989.49m | 347.63m | 8.86bn | 923.00 | 25.65 | 2.27 | -- | 8.95 | 0.7408 | 0.7408 | 2.10 | 8.37 | 0.213 | 1.93 | 3.03 | 1,072,036.00 | 7.47 | 13.29 | 8.81 | 15.49 | 68.82 | 76.49 | 35.09 | 45.71 | 3.65 | -- | 0.0508 | 24.76 | 6.27 | 7.67 | -3.32 | 0.3556 | 27.17 | -- |
| North China Pharmaceutical Co Ltd | 10.02bn | 17.62m | 8.92bn | 10.16k | 506.33 | 1.67 | -- | 0.8906 | 0.0103 | 0.0103 | 5.84 | 3.11 | 0.4693 | 2.71 | 4.31 | 986,082.90 | 0.3543 | -0.2978 | 0.8122 | -0.7042 | 30.26 | 35.73 | 0.755 | -0.5985 | 0.5425 | 1.43 | 0.6473 | -- | -3.62 | 1.89 | 100.71 | -49.62 | 4.22 | -19.73 |
| Shenzhen Chipscreen Biosciences Co Ltd | 547.79m | 103.01m | 9.21bn | 1.06k | 86.89 | 5.40 | -- | 16.82 | 0.2578 | 0.2578 | 1.33 | 4.15 | 0.1761 | 1.66 | 3.97 | 518,248.70 | 2.14 | 1.32 | 2.61 | 1.54 | 86.99 | 93.29 | 12.17 | 6.97 | 2.99 | -- | 0.4037 | 0.00 | -1.18 | 28.81 | 408.09 | 23.31 | 10.23 | -- |
| Jianmin Pharmaceutical Group Co Ltd | 4.17bn | 521.42m | 9.23bn | 2.50k | 17.66 | 3.92 | -- | 2.21 | 3.41 | 3.41 | 27.26 | 15.35 | 1.04 | 5.81 | 4.34 | 1,669,960.00 | 13.09 | 10.87 | 23.66 | 19.11 | 43.70 | 43.04 | 12.56 | 9.32 | 1.26 | -- | 0.1891 | 37.15 | 15.72 | 14.28 | 27.78 | 45.05 | 8.77 | 43.10 |
Data as of May 20 2024. Currency figures normalised to Vcanbio Cell & Gene Engineering Corp Ltd's reporting currency: Chinese Yuan Renminbi CNY
4.41%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Asset Management Switzerland AGas of 30 Sep 2022 | 11.85m | 2.53% |
| China Universal Asset Management Co., Ltd.as of 30 Sep 2022 | 2.67m | 0.57% |
| Wanjia Asset Management Co., Ltd.as of 31 Dec 2023 | 1.48m | 0.32% |
| The Vanguard Group, Inc.as of 09 May 2024 | 1.36m | 0.29% |
| Maxwealth Fund Management Co., Ltd.as of 30 Jun 2023 | 1.24m | 0.27% |
| China Asset Management Co., Ltd.as of 30 Jun 2023 | 613.40k | 0.13% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2023 | 581.50k | 0.12% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2023 | 307.10k | 0.07% |
| E Fund Management Co., Ltd.as of 30 Jun 2023 | 300.12k | 0.06% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 238.00k | 0.05% |
More ▼
Data from 31 Dec 2023 - 29 Apr 2024Source: FactSet Research Systems Inc.
